{"Clinical Trial ID": "NCT00080301", "Intervention": ["INTERVENTION 1:", "Ixabepilone + Capecitabine", "Ixabepilone 40 mg/m2 administered as a 3-hour intravenous infusion (IV) on day 1 of each 21-day cycle plus oral capecitabine 1000 mg/m2 twice daily (IDB) x 14 days", "INTERVENTION 2:", "- Capecitabine", "- Capecitabine 1250 mg/m2 BID x 14 days"], "Eligibility": ["Patients should have received 2 or 3 prior chemotherapy, including adjuvant or neoadjuvant therapy.", "A prior treatment should have included both an anthracycline (i.e. doxorubicin or epirubin) and a taxane (i.e. paclitaxel or docetaxel).", "Patients should have received a minimum cumulative dose of anthracycline or should be resistant to anthracycline.", "Patients should be resistant to taxane treatment.", "Patients cannot have a history of brain metastases and/or leptomenates.", "Patients cannot have Grade 2 or higher CTC neuropathy (motor or sensory).", "Patients may not have already received epothilone and/or capecitabine (i.e., Xeloda)"], "Results": ["Performance measures:", "\u00b7 Progression-free survival (PFS) by Independent Radiology Review Committee (IRRC)", "Patients who died without previously reported progression were considered to have progressed at the date of death; those who did not progress or died were censored at the date of the last tumour evaluation.", "Time frame: based on evaluations every 6 weeks during treatment until documented disease progression/ unacceptable toxicity", "Results 1:", "Title of the arm/group: Ixabepilone + Capecitabine", "Ixabepilone 40 mg/m2 administered as a 3-hour intravenous infusion (IV) on day 1 of each 21-day cycle plus oral capecitabine 1000 mg/m2 twice daily (IDB) x 14 days", "Total number of participants analysed: 375", "Median (95% confidence interval)", "Unit of measure: Month 5.85 (5.45 to 6.97)", "Results 2:", "Title of the arm/group: Capecitabine", "Description of the arm/group: Capecitabine 1250 mg/m2 BID x 14 days", "Total number of participants analysed: 377", "Median (95% confidence interval)", "Unit of measure: Month 4.17 (3.81 to 4.50)"], "Adverse Events": ["Undesirable Events 1:", "Total: 127/368 (34.51 per cent)", "ANAEMIA 3/368 (0.82%)", "LEUKOPENIA 0/368 (0.00 %)", "NEUTROPENIA 0/368 (0.00 %)", "COAGULOPATHY 3/368 (0.82%)", "LYMPHADENOPATHY 0/368 (0.00 %)", "THROMBOCYTOPENIA 2/368 (0.54%)", "OBLIGATORY GOODS LEAFLET 0/368 (0.00 %)", "NEUTROPENIA FEBRILE 4/368 (1.09%)", "DIFFUSION OF INTRAVASCULAR COAGULATION 0/368 (0.00 %)", "0/368 (0.00 %)", "- CARDIAC ARREST 0/368 (0.00 %)", "Adverse Events 2:", "Total: 151/369 (40.92%)", "ANEMIA 11/369 (2.98%)", "LUKOPENIA 6/369 (1.63%)", "NEUTROPENIA 18/369 (4.88 %)", "COAGULOPATHY 0/369 (0.00 %)", "LYMPHADENOPATHY 1/369 (0.27%)", "THROMBOCYTOPENIA 7/369 (1.90 %)", "1/369 (0.27%)", "NEUTROPENIA FEBRILE 15/369 (4.07%)", "DIFFUSION OF INTRAVASCULAR COAGULATION 1/369 (0.27%)", "1/369 (0.27%)", "- CARDIAC ARREST 1/369 (0.27%)"]}